TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Ages eligible for study: 12 years and above; genders eligible for study: both; prior steroid use: steroid-requiring or steroid-free.~Inclusion Criteria:~* History of asthma for at least 12 months.~* For steroid-requiring patients, documented use of inhaled corticosteroid for at least 4 weeks prior to Screening Visit~* For steroid-free patients, no history of inhaled steroid asthma medication for at least 12 weeks prior to Screening Visit.~* Demonstrate FEV-1 of 60-85% of predicted normal values at Screening and Baseline Visit.~* Documented reversibility of 15% within 12 months of Screening or at Screening Visit (15% increase from pre-FEV-1 levels following albuterol inhalation or nebulized albuterol administration).~* Symptoms of Asthma during Run-in~* Females of childbearing potential must have a negative urine pregnancy test at Screening and Baseline Visits. Females are eligible only if they are not pregnant or lactating, and are either sterile, or using acceptable methods of contraception.~* Must otherwise be healthy.~* Provide written informed consent. Wishes of minors must be respected.~Exclusion Criteria:~* Life-threatening asthma within past year or during Run-In Period.~* History of systemic corticosteroid medication within 3 months before Screening Visit.~* History of omalizumab use within past 6 months.~* History of leukotriene receptor antagonist use, e.g. montelukast, within past week.~* Current evidence or history of any clinically significant disease or abnormality including uncontrolled hypertension, uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia.~* Upper or lower respiratory infection within 4 weeks prior to Screening Visit or during Run-In Period.~* Significant, non-reversible, pulmonary disease (e.g., chronic obstructive pulmonary disease \[COPD\], cystic fibrosis, bronchiectasis).~* Known Human Immunodeficiency Virus (HIV)-positive status.~* Smoking history equivalent to 10 pack years.~* Current smoking history within 12 months prior to Screening Visit.~* Current evidence or history of alcohol and/or substance abuse within 12 months prior to Screening Visit.~* Patients who are confined in institution

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): FlutiForm 100/10 μg
- 2 (Type: ACTIVE_COMPARATOR): Fluticasone 100 μg
- 3 (Type: ACTIVE_COMPARATOR): Formoterol 10 μg
- 4 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of schizophrenia by criteria of Diagnostic and Statistical Manual of Mental Diseases, 4th edition (DSM-IV)~* expected to benefit from continuous treatment with risperidone, including patients who cannot tolerate their current antipsychotic therapy or are still exhibiting symptoms~* Positive and Negative Syndrome Scale for Schizophrenia (PANSS) score between 40 and 120 at start of study (not required for patients continuing from the 2 previous studies)~Exclusion Criteria:~* Meet criteria for other psychiatric disorders or mental retardation (documented IQ \<70)~* history of substance dependence (including alcohol, but excluding nicotine and caffeine)~* hypersensitivity or intolerance to risperidone~* extrapyramidal symptoms (EPS) such as tremor that are not adequately controlled with medication

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have smoked an average of at least 10 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.~Exclusion Criteria:~* Subjects who have used bupropion, Zyban, or Wellbutrin previously.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient \> 18 years of age with diarrhea associated with a positive stool test for C. difficile toxin(s). Patients may be diagnosed with C. difficile by hospital/clinic/reference microbiology laboratory test or by a rapid diagnostic test performed by the study staff and positive test result must be within 14 days of enrollment.~2. Patient must receive standard of care treatment for C. difficile associated disease. Standard of care treatment should include either metronidazole by mouth or intravenously or vancomycin by mouth.~3. Patient or legal representative must have read, understood, and provided written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been fully explained.~Exclusion Criteria:~1. History of chronic diarrheal illness such as ulcerative colitis or Crohn's disease.~2. Score of 4 on modified Horn's index~3. Severe C. difficile colitis with planned surgery in less than 24 hours.~4. Positive pregnancy test within 24 hours of study infusion or an unwillingness to undergo pregnancy testing in females of child-bearing potential. Females capable of child-bearing must agree not to become pregnant from the time of study enrollment until at least 3 months after completion of study infusion. If a woman is sexually active and has no history of hysterectomy or tubal ligation, she must agree to use hormonal or barrier birth control with spermicidal gel.~5. Breastfeeding.~6. Receipt of other investigational study agent within previous 30 days.~7. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the patient participating in the study or make it unlikely the patient could complete the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GS-CDA1/MDX-1388 (Type: EXPERIMENTAL): Biological: GS-CDA1/MDX-1388 One Intravenous dose
- Placebo (Type: PLACEBO_COMPARATOR): Biological: normal saline (0.9% sodium chloride) One Intravenous dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy in Treating Children With Liver Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven hepatoblastoma or hepatocellular carcinoma~  * Diagnostic surgical biopsy strongly recommended for all patients and mandatory for the following:~    * Children under 6 months of age~   * Children over 3 years of age~   * Patients with a normal serum alfa-fetoprotein (alfa-FP)~ * Compatible imaging and raised serum alfa-FP level mandatory if no biopsy performed~* Standard risk disease:~  * Tumors involving no more than 3 hepatic sections~ * No extrahepatic abdominal disease~ * No metastases~* High risk disease:~  * Tumors involving all 4 hepatic sections AND/OR~ * Evidence of extrahepatic metastases or abdominal disease~* Presence or absence of metastatic disease must be documented by chest x-ray and/or lung CT scan~PATIENT CHARACTERISTICS:~Age:~* 16 and under at diagnosis~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Not specified~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* See Disease Characteristics~* Prior surgery allowed

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Seroquel in Bipolar Depression Versus SSRI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female out-patients aged 18 to 65 years inclusive~* Diagnosis of Bipolar Disorder (Bipolar I or Bipolar II), most recent episode depressed~Exclusion Criteria:~* Current period of depression lasting less than 4 weeks or more than 12 months~* Use of prohibited medication~* Substance or alcohol dependence or abuse~* Current suicide risk or suicide attempt within 6 months~* Breast feeding or pregnancy~* Clinically relevant disease or clinical finding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has a BMI \< 42 kg/m2~* Subject is taking \>1500 mg metformin per day for at least 8 weeks~* Subject has HbA1c value of 7.0% and \< 11% at screening~* Subject is willing to follow AHA weight maintaining diet and exercise program~* Subject is a nonsmoker for at least 6 months~Exclusion Criteria:~* Subject has type 1 diabetes~* Subject has a history of stroke or chronic seizure~* Subject has a history of neoplastic disease~* Subject has a history of gastrointestinal, cardiovascular, blood, liver kidney, respiratory, immunological or genitourinary disorders or diseases~* Subject is currently taking 2 or more diabetes medications~* Subject has glaucoma or is blind~* If female, subject is pregnant or breastfeeding~* Subject consumes \> 3 alcoholic beverages per day~* Subject has had major surgery or has donated blood in the last 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MK-0941
- 2 (Type: PLACEBO_COMPARATOR): Placebo Comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms of atrial fibrillation since no longer than 48 hours~* Age 18 - 90 years~Exclusion Criteria:~* Need for immediate electrical cardioversion due to hemodynamic instability (hypotension: systolic blood pressure \< 100 mmHg, dyspnea, loss of consciousness, unstable angina)~* Moderate to severe heart failure (NYHA III/IV) and patients with previously documented left ventricular ejection fraction (LVEF) ≤ 35%~* History or signs of acute coronary syndromes (acute myocardial infarction, unstable angina) within the last 30 days~* Resting ventricular rate \< 80 beats per minute without pace maker back-up~* QT interval of \> 440 milliseconds~* Wolff-Parkinson-White (WPW) syndrome~* History of Torsade de pointes arrhythmias or other polymorphic ventricular tachycardias~* Signs of thyreotoxicosis~* Sick Sinus Syndrome or atrioventricular block greater than first degree~* Severe valvular heart disease, clinically meaningful hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis~* Serious disorders of the hepatic, renal (Creatinine \> 2.5mg/dl), pulmonary, gastrointestinal, hematologic or central nervous system and serious psychiatric disorders~* Abnormal serum electrolytes despite adequate therapy (especially potassium \<3.5 mmol/l or \> 5.5 mmol/l)~* Intravenous use of other Class I or III antiarrythmic drugs within 4 hours of study drug application~* Pregnancy (a β-HCG test will be performed in all female subjects apart from women \> 50 years and with amenorrhea for at least 12 month (absence of other causes of amenorrhoea)~* Known hypersensitivity to study medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Vernakalant (Type: ACTIVE_COMPARATOR): Initially, patients will be given 3mg/kg Vernakalant in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of Vernakalant (2mg/kg), again over 10 minutes. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.
- Ibutilide (Type: ACTIVE_COMPARATOR): Patients will be given 1mg of ibutilide in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide, again over 10min. If the initial rhythm has not converted to sinus rhythm after 2 hours, consented patients will be treated with electrical cardioversion using a standard routine protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Minor Patient with alveolar proteinosis by double mutation Ala393Thr and SER567LEU of the MARS gene, genetically proven.~* Patient in need of prolonged hospitalization in Necker for treatment of bronchial-alveolar washes in the context of care.~* Patient for which methionine can be administered orally or by enteral probe (Nasogastric or gastrostomy probe)~* Signed Informed consent form by parents / legal guardian~Exclusion Criteria:~* Patient with alveolar proteinosis by other mutations of the MARS gene~* Patient with alveolar proteinosis secondary to another etiology or without identified cause~* Refusal to participate in the study~* High blood pressure requiring drug treatment~* Heart failure~* Known hypersensitivity to one of the substances used or potentially used in the study: methionine, vitamins B6, B12, B9 and C~* Pre-Hypermethioninemia (Methioninemia \> + 2 DS of normal for age) whatever the cause

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Methionine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Chinese Herbal Medicine Xiaojidaozhi Decoction in the Treatment of Childhood Constipation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of childhood constipation~2. Criteria of constipation meets the Rome IV criteria(H3a)~3. Must be able to swallow capsules~Exclusion Criteria:~1. Digestive tract diseases~2. Neurologic diseases~3. Endocrine diseases~4. Metabolic diseases~5. Gastrointestinal surgery~6. Using drugs which can take impact on bowl motility

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Xiaojidaozhi Decoction (Type: ACTIVE_COMPARATOR): Xiaojidaozhi Decoction and Fiberform and Toilet training are used for treatment of childhood Constipation
- non-Xiaojidaozhi Decoction (Type: PLACEBO_COMPARATOR): Placebo and Fiberform and Toilet training are used for treatment of childhood Constipation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* ≥ 2 prior lines of therapy which must have included at least 2 consecutive cycles of lenalidomide and a proteosome inhibitor alone or in combination~* Documented refractory or relapsed and refractory multiple myeloma~* Refractory to proteosome inhibitor and lenalidomide, and to last treatment~* Relapsed and refractory patients must have achieved at least a partial response to previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed within 6 months, and were refractory to their last treatment~* Measurable disease at screening~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2~Exclusion Criteria:~* Active plasma cell leukemia~* Prior treatment with pomalidomide~* Unable to tolerate thromboembolic prophylaxis while on the study~* Prior autologous stem cell transplant within 12 weeks~* Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elotuzumab Arm (Type: EXPERIMENTAL): Biological:Elotuzumab (BMS-901608; HuLuc63)~* Solution, Intravenous(IV),10 mg/kg(Cycles 1 and 2 weekly, on Days 1,8,15,22)~* Solution, Intravenous(IV),20 mg/kg(Cycle 3 and Beyond: Day 1)~Drug: Pomalidomide~•Capsules,Oral,4 mg,once daily, on Days 1-21~Other Name: Pomalyst~Drug: Dexamethasone~* Subjects ≤ 75 years old:~  •Tablets, Oral,28 mg, once daily on: Days 1,8,15,22(Cycles 1\&2) Day 1(Cycle 3 and Beyond)~  •Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1\&2) Day 1(Cycle 3 and Beyond)~  •Tablets, Oral,40 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)~* Subjects \> 75 years old:~  •Tablets, Oral,8 mg, once daily on: Days 1,8,15,22(Cycles 1\&2) Day 1(Cycle 3 and Beyond)~  •Solution, Intravenous(IV), 8 mg, once daily on: Days 1,8,15,22(Cycles 1\&2) Day 1(Cycle 3 and Beyond)~  •Tablets, Oral, 20 mg, once daily on: Days 8,15,22(Cycle 3 and Beyond)~Other Names:~Decadron,Dexamethasone ,Intensol,Dexpak,Taperpak
- Control Arm (Type: ACTIVE_COMPARATOR): Drug: Pomalidomide~• Capsules, Oral, 4 mg, once daily, on Days 1-21 Other Name: Pomalyst~Drug: Dexamethasone~Subjects ≤ 75 years old:~• Tablets, Oral, 40 mg, weekly on Days 1, 8, 15 and 22~Subjects \> 75 years old:~• Tablets, Oral, 20 mg, weekly on Days 1, 8, 15 and 22,~Other Names:~* Decadron~* Dexamethasone Intensol~* Dexpak~* Taperpak

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete